An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection

An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection

Morbidity and mortality attributed to Clostridium difficileinfection (CDI) have increased over the past 20 years. Currently, antibiotics are the only US FDA-approved treatment for primary C. difficile infection, and these are, ironically, associated with disease relapse and the threat of burgeoning...

Full description

Bibliographic Details
Main Authors: Gayatri Vedantam, Joshua Kochanowsky, Jason Lindsey, Michael Mallozzi, Jennifer Lising Roxas, Chelsea Adamson, Farhan Anwar, Andrew Clark, Rachel Claus-Walker, Asad Mansoor, Rebecca McQuade, Ross Calvin Monasky, Shylaja Ramamurthy, Bryan Roxas, V. K. Viswanathan
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Microbiology
Subjects:
Clostridium difficile
infectious diarrhea
synthetic biology
surface layer protein
Lactobacillus
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2018.02080/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2018.02080/full

Similar Items